Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs

Acer has notified the FDA in the resubmission that the third-party contract packaging manufacturer is ready for inspection NEWTON, MA– July 18, 2022– Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news